BioRestorative Therapies Inc. (OTCQB: BRTX), an emerging leader in autologous adult stem cell treatments for the disc/spine, metabolic disorders, and obesity, operating alongside companies like Pluristem Therapeutics Inc. (NASDAQ: PSTI) and Neuralstem Inc. (AMEX: CUR), represents a unique opportunity for investors to capitalize on the industry’s growth.
Disc Repair – Non-Surgical Alternative
BioRestorative’s primary focus in the near-term is on an advanced stem cell injection procedure designed to offer relief from bulging and herniated discs (to date over 40 procedures have been performed on patients in the U.S.). This novel therapy offers an alternative treatment designed to fill the large gap that currently exists in disc treatments between non-surgical and surgical therapies. Using a unique medical device that delivers the patients own stem cells to optimal locations, the company’s technology is a minimally invasive and non-surgical way to repair some disc/spine injuries without surgery.
According to Global Industry Analysts, the global spine surgery market is set to reach $9.3 billion by 2017, driven by rising incidences of chronic back pain, an aging population and increased awareness of spine surgery procedures. Ultimately, the Company hopes it can capture a portion of this enormous market and deliver significant value to shareholders.
“Brown Fat” for Treating and Preventing Diabetes and Obesity
In its pipeline, BioRestorative is developing its ThermoStem™ Program that is focused on treating metabolic disorders (diabetes, heart disease, etc.) and obesity by using stem cells from population of adipose (fat) tissue known as “Brown Fat.” The Company is working to develop a “Brown Fat” stem cell-based solution to potentially reduce glucose and lipid levels while inducing weight loss through a natural cellular “biologic diet” with the ultimate goal of delaying or preventing the onset of diabetes. In addition, according to a recent study at the University of Sherbrooke in Quebec, “Brown Fat” may actually burn calories at a very rapid rate, causing weight loss, by generating heat (thermogenesis).
While the ThermoStem™ Program certainly has a play in the $20 billion weight loss market, the Company is initially targeting metabolic disorders by potentially developing a protocol to lower blood glucose and lipid levels. These markets represent multi billion dollar industries that combine to form a significant opportunity.
Unique Business Model
BioRestorative employs a unique “hybrid” business model with both near-term and long-term revenue opportunities. According to management in an interview, the Company indicated that it could immediately license and sell its disc/spine technology outside of the U.S. (while it fine-tunes its pre-clinical work) and plans on generating revenues as early as this year.
In the end, the Company’s approach to these two enormous markets, combined with its unique business model, make it a compelling investment opportunity at these levels. With a market capitalization of just $18.14 million, there is clearly significant upside potential in the stock over the coming quarters and years.